How to Improve Your GlycoMark (1,5-AG) Level: Evidence-Based Strategies

What GlycoMark (1,5-AG) Actually Measures

GlycoMark reports serum 1,5-anhydroglucitol, a six-carbon sugar found in most foods. Under normal conditions the kidneys reabsorb nearly all of it. When blood glucose rises above roughly 180 mg/dL, glucose competes with 1,5-AG for reabsorption in the renal tubules, and 1,5-AG spills into urine instead. Serum levels fall as a result. Because the body's 1,5-AG pool is replenished steadily from the diet and reabsorption recovers once glucose normalizes, the level behaves like a rolling record of recent hyperglycemic episodes rather than a single-point measurement.

How 1,5-AG Differs from HbA1c

HbA1c reflects average glucose over roughly 2 to 3 months. It cannot tell the difference between someone with steady glucose near 154 mg/dL and someone swinging between 80 and 280 mg/dL, even though both could post the same 7.0% result. Dungan and colleagues compared 1,5-AG against continuous glucose monitoring data in patients with moderately controlled type 2 diabetes and found a significant inverse relationship between 1,5-AG and postprandial glucose peaks in patients whose HbA1c was under 8.0%, while HbA1c itself did not correlate with those peaks in the same group [1]. That gap is the practical reason to use 1,5-AG alongside HbA1c rather than instead of it, particularly when a patient's symptoms or complications seem out of step with an otherwise reasonable A1c.

The Renal Threshold Connection

The renal glucose threshold averages around 180 mg/dL but varies between individuals, roughly 160 to 200 mg/dL. Every excursion above an individual's threshold draws down the 1,5-AG pool a little further. Research on glucose fluctuation and oxidative stress, including work by Monnier and colleagues published in JAMA, found that markers of oxidative stress tracked more closely with glucose swings than with mean glucose or HbA1c in people with type 2 diabetes [2]. That is one of the mechanistic arguments for treating variability, not just averages, as clinically relevant, and it is the reason a marker like 1,5-AG has a role beyond fasting glucose and HbA1c.

Normal GlycoMark (1,5-AG) Ranges and Interpretation

Reference ranges vary by lab and assay, but a commonly cited range for someone without diabetes is roughly 10.7 to 32.0 mcg/mL. Men tend to run slightly higher than women. Because ranges differ between labs, use the reference interval printed on your own report rather than a single number pulled from any one source.

What the Numbers Mean

Results above roughly 10.7 mcg/mL generally suggest infrequent excursions past the renal threshold, while lower values suggest more frequent or more severe post-meal spikes. Early validation work on the assay, including work by Buse and colleagues, associated lower 1,5-AG values with a greater proportion of time spent above 180 mg/dL on continuous glucose monitoring [3]. The exact cutoff that corresponds to a specific percentage of time in hyperglycemia has not been rigorously standardized across labs and populations, so treat any single-number threshold as a general guide to discuss with your clinician rather than a precise clinical rule.

When 1,5-AG Is Unreliable

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) work by lowering the renal threshold for glucose reabsorption on purpose, which pushes glucose, and along with it 1,5-AG, into the urine at lower blood glucose levels than usual. A patient on an SGLT2 inhibitor can show a low 1,5-AG even with genuinely well-controlled glucose. Manufacturer and clinical laboratory guidance is consistent that GlycoMark should not be used to judge glycemic control in patients taking this drug class. Pregnancy and advanced chronic kidney disease (eGFR under roughly 30 mL/min/1.73m²) also distort the result and are discussed further below.

Why Raising a Low 1,5-AG Matters

A low 1,5-AG is a signal of glycemic variability, and variability carries research interest independent of average glucose, though the strength of that evidence differs by outcome.

Glycemic Variability and Vascular Risk

The HEART2D trial randomized patients with type 2 diabetes and a recent heart attack to a prandial insulin strategy targeting after-meal glucose or a basal insulin strategy targeting fasting glucose. The trial's primary composite cardiovascular endpoint did not differ significantly between groups, meaning it did not prove that targeting postprandial glucose reduces cardiovascular events. A prespecified subgroup analysis did find fewer cardiovascular events among patients with lower measured glycemic variability, which is hypothesis-generating rather than confirmatory [4]. Take the finding as supporting the general principle that variability may matter, not as proof that any specific intervention lowers cardiovascular risk.

The Clinical Case for Tracking 1,5-AG

Professional endocrinology guidance recognizes that postprandial glucose patterns can contribute to cardiovascular risk in ways that HbA1c alone does not capture, and that postprandial patterns deserve attention when a patient's clinical course does not match their A1c [5]. For someone with an HbA1c of 7.0% to 8.0% who still has symptoms or unexplained complications, a low 1,5-AG can help explain the discrepancy and point toward postprandial-focused treatment changes, which is a conversation to have with the prescribing clinician rather than a self-directed decision.

Medication Strategies That May Raise 1,5-AG

Raising 1,5-AG means reducing excursions above the renal threshold. Several drug classes act specifically on the postprandial glucose curve, but any medication change is a decision for the prescribing clinician, not something to start or adjust independently.

GLP-1 Receptor Agonists

Semaglutide, liraglutide, and dulaglutide slow gastric emptying and suppress glucagon, both of which blunt post-meal glucose rises, so the drug class is mechanistically well suited to improving 1,5-AG even though 1,5-AG was not the outcome measured in the major cardiovascular trials of these drugs. The SUSTAIN-6 trial of semaglutide showed roughly a 1.4 percentage point HbA1c reduction along with cardiovascular benefit, but it did not report a postprandial-specific or 1,5-AG endpoint, so the postprandial effect described here is based on drug mechanism rather than a trial result [6]. Patients switching to a GLP-1 agonist sometimes see 1,5-AG rise over several weeks as post-meal peaks flatten, but individual response varies.

Prandial Insulin and Rapid-Acting Analogs

Rapid-acting insulins (lispro, aspart, glulisine) given before meals target postprandial spikes directly, and timing matters: dosing closer to the start of the meal rather than well after eating has begun has been associated with better postprandial control in clinical research, including work by Cobry and colleagues [7]. The exact magnitude of benefit depends on the individual and the meal, so this is a topic for a conversation with your prescriber about bolus timing rather than a fixed number to target on your own.

Alpha-Glucosidase Inhibitors

Acarbose slows carbohydrate digestion in the small intestine and flattens the postprandial curve directly. In the STOP-NIDDM trial of patients with impaired glucose tolerance, acarbose reduced 2-hour postprandial glucose and was associated with roughly a 49% relative risk reduction in new cardiovascular events compared with placebo [8]. It is used less often in the United States because of gastrointestinal side effects, but it remains a legitimate option specifically for postprandial hyperglycemia.

DPP-4 Inhibitors

Sitagliptin, saxagliptin, and linagliptin raise endogenous incretin activity and produce a smaller postprandial effect than GLP-1 agonists, but a measurable one. Small studies of sitagliptin in Japanese patients with type 2 diabetes have reported an increase in 1,5-AG over roughly 12 weeks of treatment, though this evidence is limited and preliminary. The exact magnitude reported in that study is modest and population-specific, so treat it as evidence that this drug class can move 1,5-AG in the right direction rather than as a number to expect in every patient.

Dietary Strategies to Reduce Postprandial Spikes

Medication is one lever. Food composition, portion size, and meal structure are others, and for many patients these changes are the first thing to try before a medication adjustment.

Macronutrient Sequencing

A small crossover study by Shukla and colleagues (11 participants) found that eating protein and vegetables before carbohydrates at the same meal lowered postprandial glucose and insulin increments compared with eating carbohydrates first, and a follow-up study from the same group found the effect held up over a longer intervention [10]. The sample size in the original study is small, so treat the exact percentage improvements as illustrative rather than a number every patient will replicate, but the direction of the effect, that food order changes the postprandial curve, is consistent with what is understood about how fat and protein slow gastric emptying.

Glycemic Index and Glycemic Load

Choosing lower glycemic index carbohydrates can reduce the size of postprandial peaks. The American Diabetes Association's Standards of Care describes substituting lower glycemic load foods for higher glycemic load foods as a step that may modestly improve glycemic control [11]. Practical swaps include steel-cut oats instead of instant oats, or lentils instead of white rice.

Fiber Intake

Soluble fiber from sources such as psyllium, oat beta-glucan, and legumes slows glucose absorption. A large pooled analysis of prospective studies by Reynolds and colleagues, published in The Lancet, found that higher dietary fiber intake was associated with reduced risk of type 2 diabetes and cardiovascular mortality across the studies analyzed, with the size of the association varying by outcome [12]. For someone focused on postprandial spikes specifically, adding soluble fiber to a high-carbohydrate meal is a reasonable, low-risk step, though the Lancet analysis was measuring long-term disease outcomes rather than short-term 1,5-AG change.

Portion Control and Meal Frequency

Smaller, more evenly spread carbohydrate portions across the day reduce the chance that any single meal drives glucose above 180 mg/dL. A commonly used starting point in clinical practice is roughly 30 to 45 g of carbohydrate per meal, then adjusting based on your own CGM data or 1- and 2-hour postprandial fingerstick readings. This is a practical starting heuristic rather than a number backed by a specific trial, and your own post-meal readings should override it.

Exercise Timing and 1,5-AG

Physical activity lowers glucose partly through insulin-independent glucose uptake into skeletal muscle. When you move relative to a meal changes how much that activity blunts the postprandial spike.

Post-Meal Walking

A randomized trial by DiPietro and colleagues found that three 15-minute walks after each main meal reduced 24-hour postprandial glucose more than a single 45-minute walk taken at another time of day, in older adults with prediabetes or type 2 diabetes [13]. The practical takeaway is that a short walk timed to start after eating appears to matter more than the same total activity done at a time disconnected from meals.

Resistance Training

Resistance exercise improves insulin sensitivity for roughly 24 to 72 hours after a session. The American Diabetes Association's Standards of Care recommend at least two sessions of resistance training per week for adults with type 2 diabetes [11]. Over months, added lean mass increases baseline glucose disposal, which can reduce the frequency and height of postprandial peaks, though this is a slower, cumulative effect rather than something that shows up after one session.

A Practical Weekly Template

Combining both approaches is a reasonable starting point: resistance training two to three times a week, plus a short walk after larger meals. If you use a CGM, you can watch the direct relationship between post-meal movement and a flatter glucose curve, which is often the most motivating feedback available.

Monitoring Your Progress

Because 1,5-AG reflects a 1- to 2-week window, you can see the effect of a change faster than you can with HbA1c.

Repeat Testing Intervals

Clinicians commonly recheck 1,5-AG every 2 to 4 weeks during active adjustment of medication or lifestyle habits, which is faster feedback than the roughly 3 months needed for a new HbA1c to reflect a change. Once 1,5-AG stabilizes above the lower end of the reference range, testing every 3 to 6 months alongside HbA1c is a reasonable cadence, though your clinician may adjust this based on your overall picture.

Pairing with CGM Data

Continuous glucose monitors provide the real-time data that explains a 1,5-AG trend. Time in range (TIR), usually defined as 70 to 180 mg/dL, moves in the opposite direction from 1,5-AG depletion: more time above 180 mg/dL means more 1,5-AG loss. The International Consensus on Time in Range recommended a TIR target above 70% for most adults with diabetes, and later work has validated TIR as a meaningful outcome measure in its own right [14][15]. If your TIR improves over a few weeks, expect 1,5-AG to follow with some lag.

When to Reassess Your Approach

If 1,5-AG has not improved after 4 to 6 weeks of a genuine intervention, it is worth checking a short list of things before assuming the strategy has failed: medication timing and dosing, the carbohydrate content of your largest meal, whether exercise is actually timed after meals, and whether an SGLT2 inhibitor is confounding the reading. As diabetes specialist Dr. Irl Hirsch has written, 1,5-AG is most useful for identifying glycemic variability that HbA1c cannot explain, but pharmacologic confounders should be ruled out before drawing conclusions from the number [16].

Special Populations and Considerations

Not every patient should be assessed or managed the same way using 1,5-AG.

Type 1 Diabetes

People with type 1 diabetes often experience wider glucose swings than those with type 2, and because 1,5-AG reflects short-term excursions, it could plausibly add information beyond HbA1c in this population. That said, the evidence base establishing 1,5-AG's specific role in type 1 diabetes management is thinner than in type 2 diabetes, and CGM-derived variability metrics such as TIR and coefficient of variation are generally better validated for this purpose. Treat 1,5-AG as a secondary data point in type 1 diabetes, and lean on CGM data and your endocrinology team's judgment first.

Pregnancy

Gestational diabetes management targets postprandial glucose under 140 mg/dL at 1 hour and under 120 mg/dL at 2 hours per ACOG guidance [17]. The renal glucose threshold decreases during pregnancy, so 1,5-AG drops at lower glucose levels than it would outside pregnancy, making the test unreliable for this population. Self-monitored blood glucose and CGM remain the tools to rely on during pregnancy, not 1,5-AG.

Chronic Kidney Disease

Impaired renal tubular function alters how the kidneys handle 1,5-AG, so patients with an eGFR under roughly 45 mL/min/1.73m² may show falsely low or inconsistent values. HbA1c, or glycated albumin for patients on dialysis, remains the preferred glycemic metric in advanced CKD [18].

A Decision Framework for a Low or Confusing GlycoMark Result

The right response to a low 1,5-AG depends on a small number of facts about your situation. Use this table with your clinician rather than as a self-diagnosis tool.

Putting It Together

A reasonable starting approach: use a CGM for at least 14 days to see which meals produce the largest spikes, target those meals first with food order changes, a carbohydrate portion closer to 30 to 45 g, and a short walk afterward, then recheck 1,5-AG around 4 weeks. If lifestyle changes alone do not bring postprandial peaks below 180 mg/dL, that is the point to discuss a GLP-1 agonist, prandial insulin, or acarbose with your prescriber rather than continuing to adjust lifestyle factors alone.